From a biomarker-driven strategy to delay or avoid cystectomy, to practice-changing perioperative immunotherapy, developments ...

NEW YORK, NY - May 23, 2025 ( NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN).

Among the companies displaying the strength of Chinese research in oncology at the 2025 ASCO Annual Meeting will be Hutchmed.

On day 2 of an FDA advisory meeting to consider a new treatment for non–muscle invasive bladder cancer, an FDA official warns ...

The growing demand for Foley catheters is driven by several important factors. Firstly, the rising global aging population is contributing to a highe ...

An FDA advisory committee on Wednesday unanimously voted against recommending approval of the PARP inhibitor talazoparib ...

CG Oncology stock surges 27% in a month following superior efficacy data from its phase III study of cretostimogene for a bladder cancer indication.

We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized ...

UroGen Pharma (URGN) stock falls as the company faces a major setback after an FDA panel votes against its bladder cancer ...

Orionis Biosciences Inc. is sticking with Genentech Inc. in a second deal to discover small-molecule monovalent glue therapies for treating cancer. Privately held Orionis is getting $105 million up ...

Anglo-Swedish pharma major AstraZeneca reports that it will have a historic presence at this year’s American Society of ...

Roger Li, MD, discusses the MoonRISe-1 study evaluating TAR-210 in FGFR-altered intermediate-risk non-muscle-invasive bladder ...